Privigen Shows Improved Function for CIDP Patient

Posted on

CSL Behring logo

CSL Behring reports that data presented from the Privigen Impact on Mobility and Autonomy (PRIMA) trial at the Peripheral Nerve Society Inflammatory Neuropathy Consortium Meeting in Rotterdam, Netherlands, suggests that treatment with Privigen®, an intravenous immunoglobulin (IVIg), may lead to improvement in function in CIDP patients.

Click here to learn more.